title: Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
abstract: Purpose To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). Patients and Methods Eligible patients with advanced CD117-positive GIST from 56 institutions in 13 countries were randomly assigned to receive either imatinib 400 mg or 800 mg daily. Patients on the 400-mg arm were allowed to cross over to 800 mg upon progression. Results Between February 2001 and February 2002, 946 patients were accrued. Median age was 60 years (range, 18 to 91 years). Median follow-up time was 10.9 years. Median progression-free survival times were 1.7 and 2.0 years in the 400- and 800-mg arms, respectively (hazard ratio, 0.91; P = .18), and median overall survival time was 3.9 years in both treatment arms. The estimated 10-year progression-free survival rates were 9.5% and 9.2% for the 400- and 800-mg arms, respectively, and the estimated 10-year overall survival rates were 19.4% and 21.5%, respectively. At multivariable analysis, age (< 60 years), performance status (0 v ≥ 1), size of the largest lesion (smaller), and KIT mutation (exon 11) were significant prognostic factors for the probability of surviving beyond 10 years. Conclusion This trial was carried out on a worldwide intergroup basis, at the beginning of the learning curve of the use of imatinib, in a large population of patients with advanced GIST. With a long follow-up, 6% of patients are long-term progression free and 13% are survivors. Among clinical prognostic factors, only performance status, KIT mutation, and size of largest lesion predicted long-term outcome, likely pointing to a lower burden of disease. Genomic and/or immune profiling could help understand long-term survivorship. Addressing secondary resistance remains a therapeutic challenge.
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Paolo G
authors.initials: PG
authors.lastname: Casali
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: John
authors.initials: J
authors.lastname: Zalcberg
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Axel
authors.initials: A
authors.lastname: Le Cesne
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Peter
authors.initials: P
authors.lastname: Reichardt
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Lars H
authors.initials: LH
authors.lastname: Lindner
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Ian R
authors.initials: IR
authors.lastname: Judson
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Patrick
authors.initials: P
authors.lastname: Schöffski
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Serge
authors.initials: S
authors.lastname: Leyvraz
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Antoine
authors.initials: A
authors.lastname: Italiano
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Viktor
authors.initials: V
authors.lastname: Grünwald
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Antonio Lopez
authors.initials: AL
authors.lastname: Pousa
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Dusan
authors.initials: D
authors.lastname: Kotasek
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Stefan
authors.initials: S
authors.lastname: Sleijfer
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Jan M
authors.initials: JM
authors.lastname: Kerst
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Rutkowski
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Elena
authors.initials: E
authors.lastname: Fumagalli
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Pancras
authors.initials: P
authors.lastname: Hogendoorn
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Saskia
authors.initials: S
authors.lastname: Litière
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Marreaud
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Winette
authors.initials: W
authors.lastname: van der Graaf
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gronchi
authors.affiliation: Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
authors.forename: Jaap
authors.initials: J
authors.lastname: Verweij
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018592:Cross-Over Studies; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate